• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


             

OSB Lead-Chronic Lead Performance


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Application Number P080006 S002/ PAS001
Current Plan Approved 04/01/2011
Study Name OSB Lead-Chronic Lead Performance
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source Sponsor Registry
Comparison Group Objective Performance Criterion
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21


OSB Lead-Chronic Lead Performance Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
six month report 09/30/2011 09/28/2011 On Time
one year report 03/31/2012 03/26/2012 On Time
18 month report 09/29/2012 09/27/2012 On Time
two year report 03/31/2013 03/28/2013 On Time
30 month report 09/29/2013 09/27/2013 On Time
three year report 03/31/2014 03/21/2014 On Time
42 month report 09/29/2014 09/24/2014 On Time
four year report 03/31/2015 03/16/2015 On Time
54 month report 09/29/2015 09/22/2015 On Time
five year report 03/30/2016 03/25/2016 On Time
66 month report 09/30/2016 09/28/2016 On Time
six year report 03/30/2017    


Contact Us

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD
20993-0002

Phone: (301) 796-6134
Fax: (301) 847-8140
julie.unger@fda.hhs.gov

Related Links

-
-